TM Editors’ Note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.
Shares of Isoray (ISR) soared 93% after the company reported long term results from a lung cancer study that recruited high risk patients. The company has developed a drug compound known as Cesium-131 seeds which it uses to fight many various types of cancer. The results showed that the Cesium-131 was able to control the tumor with a 96% success rate and in addition allow the patients 100% survival at the 5 year mark. The CEO Dwiight Babcock mentions the results in this quote:
“We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking better solutions and outcomes for their patients. We are continuing to develop our product offerings internally with support from these industry leaders. With every success that has been reported, the medical community is rapidly becoming aware of the innovative alternative our Cesium-131 products offer to cancer patients.”
Cesium-131 is Isoray’s main drug that is also known as brachytherapy, which is a focused on implanting radioisotope seeds in the tumor of the patient’s body. This is a more focused cancer treatment that has been reduced to lighter toxicity over the years. This means the drug seed is still powerful enough to kill the cancer but does not have the same toxicity as in the past when it was developed first back in the 1960s. In addition now the therapy has been modified to be faster than ever before.
